GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » EV-to-EBITDA

Telesis Bio (Telesis Bio) EV-to-EBITDA : -1.34 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telesis Bio's enterprise value is $54.46 Mil. Telesis Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-40.49 Mil. Therefore, Telesis Bio's EV-to-EBITDA for today is -1.34.

The historical rank and industry rank for Telesis Bio's EV-to-EBITDA or its related term are showing as below:

TBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.95   Med: -1.49   Max: 0.41
Current: -1.34

During the past 5 years, the highest EV-to-EBITDA of Telesis Bio was 0.41. The lowest was -26.95. And the median was -1.49.

TBIO's EV-to-EBITDA is ranked worse than
100% of 484 companies
in the Medical Devices & Instruments industry
Industry Median: 16.27 vs TBIO: -1.34

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-07), Telesis Bio's stock price is $0.3399. Telesis Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.630. Therefore, Telesis Bio's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Telesis Bio EV-to-EBITDA Historical Data

The historical data trend for Telesis Bio's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio EV-to-EBITDA Chart

Telesis Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -6.98 -0.31 -1.40

Telesis Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -2.48 -2.26 -2.13 -1.40

Competitive Comparison of Telesis Bio's EV-to-EBITDA

For the Medical Devices subindustry, Telesis Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telesis Bio's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Telesis Bio's EV-to-EBITDA falls into.



Telesis Bio EV-to-EBITDA Calculation

Telesis Bio's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=54.456/-40.493
=-1.34

Telesis Bio's current Enterprise Value is $54.46 Mil.
Telesis Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telesis Bio  (NAS:TBIO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Telesis Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3399/-1.630
=At Loss

Telesis Bio's share price for today is $0.3399.
Telesis Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.630.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Telesis Bio EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Telesis Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Telesis Bio (Telesis Bio) Business Description

Traded in Other Exchanges
N/A
Address
10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.
Executives
Gregory J. Herrema director 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers 10 percent owner GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p. 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider director, 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister director, 10 percent owner 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler officer: Chief Legal Officer C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson officer: Chief Technology Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson director, 10 percent owner, officer: President & CEO C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser officer: Chief Operating Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814